ECE2023 Report
We attended the ECE2023 in Istanbul virtually this year and were very pleased to see parathyroid conditions so well represented. We report the main sessions below. In the first Meet the Expert session Professor… [Read More]
Latest News
Endocrine Academy Report
This week Parathyroid UK attended the Society for Endocrinology’s Clinical update training programme for recently appointed consultants in diabetes and endocrinology. It provides an update on current clinical practice and offers delegates an unparalleled opportunity… [Read More]
SfE National Clinical Cases 2023
On Friday 24th March we attended the Society of Endocrinology National Clinical Cases at the RSM in London. This is a training day for endocrinologists who have the chance to showcase their work in the… [Read More]
NIFTy trial now recruiting for people having thyroid surgery
The NIFTy trial is now recruiting in several hospitals around the UK until 31/12/2023. It is open to people who are having total thyroid surgery, to remove the whole thyroid, or completion surgery to remove… [Read More]
Conference Reports 2022
Society for Endocrinology (SfE) Endocrine Academy Birmingham, April 2022 Jane & Steve Compton Jane writes: We had a brisk and busy first day with lots of interest in our leaflets and our poster below: ‘How… [Read More]
Hypopara Patient Forum summary
The European Society for Endocrinology (ESE) have produced an excellent poster summarising data from the 1st Hypoparathyroidism Patient Forum – summary, a major global event which was held online in March and presented by patient… [Read More]
National audit on hypopara published
Our national audit on the management of chronic hypoparathyroidism is now out now in print, in the latest issue of Clinical Endocrinology. Findings show a clear need for improvement, supporting the findings of the GIRFT… [Read More]
Positive results on new drug from Amolyt
Amolyt Pharma have announced positive results from the second patient cohort of their Phase 2a Clinical Trial investigating AZP-3601 as a potential treatment for hypoparathyroidism . Amolyt say “We’re excited to be one step closer… [Read More]
BAETS 2022
We were delighted to attend BAETS 2022 in person at last. Huge thanks to our two fantastic volunteers Lucy Weigall and Caroline Dow who spent two days representing hypopara and hyperpara patients at the British… [Read More]
Natpar to be discontinued
Oct 4th 2022. Takeda will be discontinuing Natpar globally at the end of 2024. Supply for current patients will be maintained until then and beyond until stock is depleted. Having worked since 2009 to get… [Read More]